Significance of activation of neurohumonal regulation systems in clinics and treatment of chronic heart failure (CHF) is in world literature data, that should be considered when applying angiotensin-converting enzyme inhibitors in treatment of patients suffering from CHF. Each of components of the metabolic syndrome (MS) is a well-known risk factor of CHF, and high atherogenicity of their clustering seems to be due to their metabolic interrelationships. A screening of CHF in patients with MS has been done. Echocardiographic criteria of left ventricle myocardial dysfunction were studied. One can see the positive effect of lisinopril on the functional state of left ventricle.
